



Fulcrum Therapeutics Announces \$80 million Series B Financing

Proceeds will help advance lead program in facioscapulohumeral muscular dystrophy (FSHD) and further support advancement of rare disease-focused pipeline

Cambridge, Mass., September 5, 2018 – [Fulcrum Therapeutics](#), a company focused on discovering and developing small molecule therapies to unlock gene control and treat serious genetic diseases, today announced the closing of an \$80 million Series B financing. Proceeds from the financing will be used to advance Fulcrum’s lead program in facioscapulohumeral muscular dystrophy (FSHD) into clinical testing, and to progress its pipeline of therapeutics for rare, genetically based neuromuscular, central nervous system and hematologic disorders.

The financing was led by Foresite Capital, with participation by [Fidelity Management and Research Company, 6 Dimensions Capital, Casdin Capital, Sanofi Ventures, Section 32, NS Investments, entities affiliated with Leerink Partners, and undisclosed institutional investors. Jim Tananbaum, M.D., of Foresite Capital will join the Board of Directors of Fulcrum.

“We are delighted to have the support of this exceptional group of investors as we continue to work towards our vision of bringing new futures to patients and families affected by debilitating genetic diseases,” said Robert J. Gould, Ph.D., Fulcrum’s President and Chief Executive Officer. “This funding will provide crucial support as we move rapidly towards the clinic with our lead drug candidate in FSHD, and further advance our pipeline of small molecule therapies.”

Fulcrum is pioneering a small molecule, precision medicine approach to address severe monogenic and prevalent diseases of gene misregulation. By focusing on disease-causative genes, the company is unlocking the druggable mechanisms that regulate disease to develop a new generation of therapies in multiple therapeutic areas. In partnership with the FSHD Clinical Trial Research Network (CTRN), the company has initiated a clinical trial readiness study in FSHD. The aim of the study is to standardize a set of tools and measurements for Fulcrum’s future clinical drug trials.

“Fulcrum’s uniquely patient-centered approach to treating severe genetic diseases is already delivering strong early results,” said Dr. Tananbaum. “We are confident that Fulcrum will continue to lead the way in developing novel medicines for patients and families who have no viable treatment options, and we look forward to supporting the team as it works to further advance its rare-disease focused pipeline.”

About Fulcrum Therapeutics

Fulcrum Therapeutics is a biotechnology company developing new medicines to deliver a new future to patients and their families by transforming gene regulation in disease. Fulcrum's therapies are based on modulating gene regulation via control of genetic on and off switches of disease genes. Fulcrum, headquartered in Cambridge, Mass., was launched by Third Rock Ventures in 2016 and named a "Fierce 15" company later that year. For more information, please visit www.fulcrumtx.com.

CONTACTS:

Media:

Sarah Sutton

Ten Bridge Communications

sarah@tenbridgecommunications.com

518-932-3680